Showing 1 to 15 of 125 entries
SELL
Good time to sell the stock. Has sold shares. Doesn't see positive upside for the stock. Numbers of the surface (dividend yield, cash flow yield) look good. Problem is that one of major drugs loses patent next year. Building pipeline of R&D in consumer drugs.
0
BUY
A great CEO. Pays a 4% yield. He isn't worried about Humira coming off patent, because they have a lot of cash.
0
BUY
He likes healthcare and likes their 4.1% dividend. It's cheap at 10x earnings. There are concerns about their big drug coming off patent, but management can transition their main drug coming off patent.
0
BUY
Reported a mix quarter today. Though shares are down today, it's still up 5% YTD. AbbVie re-affirmed guidance. She wouldn't read too much into the quarter.
0
BUY
Healthcare is his favourite defensive sector. AbbVie needs to provide clear guidance about the erosion curve in Humira, its top drug (that will go off-patent next year). A popular drug going generic isn't necessarily a death sentence for the stock. He thinks management can pull this off. Sales declined only slightly, despite a 40% drop in Humira. Today, they announced a $2.2 billion settlement in opiod litigation (the opiod epidemic) which removes that overhang. It's probably a pretty good buy here.
0
BUY
A great name in pharma that reported today. Their neuroscience division is up 14% quarter over quarter, while cash flow yield is above 7%. It's performed relatively well vs. the market YTD. He still likes the name.
0
BUY
His long-term concern comes out of Washington which is proposing drug-pricing laws. One mixed quarter doesn't worry him; the stock has been a war horse. AbbVie proves it can refill its pipeline.
0
BUY
Allan Tong’s Discover Picks When I last recommended AbbVie in mid-April, this popular dividend-payer was trading at 52-week highs nearing $175. In three months, shares had raced from $135, so $175 was unsustainable. Last month, shares dipped below $138 and since then it has trended around a reasonable $150. I still like AbbVie stocks. It pays a solid 3.75% dividend, trades below 22x earnings, is safe at a 0.75 beta in a rockly market, and its shares have risen 120% in five years. Read Our 3 defensive healthcare stocks picks for our full analysis.
0
WEAK BUY
It's one of the big healthcare stocks, a sector he likes. The issue here is that their big drug is coming off patent this year. Not sure how this will go. Be cautious in the coming year. The stock could be weak. Great dividend and drug pipeline, though.
0
BUY
Pays a 4% yield and just started working on this Allergen franchise they just bought. Their core drugs keep selling. This will go higher.
0
SELL
Largest drug going off patent, already seeing bio-similars. Earnings will go dormant.
0
BUY
Operates at almost 8% free cash flow yield. Pays a 3.7% yield.
0
COMMENT
Biotechs have strong balance sheets, better than a few years ago. Likes this as well as Amgen. Better to buy individual biotech stocks over ETFs. He has options calls on Abbvie.
0
BUY
Is an innovative pharma company. Life sciences companies are getting more interest from investors.
0
BUY
People want cash flow and now cash burn now. Biotech is bouncing like cryptos. You can buy this of IBB, but there are huge opportunities in biotech.
0
Showing 1 to 15 of 125 entries

AbbVie Inc.(ABBV-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 30

Neutral - Hold Signals / Votes : 3

Bearish - Sell Signals / Votes : 7

Total Signals / Votes : 40

Stockchase rating for AbbVie Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

AbbVie Inc.(ABBV-N) Frequently Asked Questions

What is AbbVie Inc. stock symbol?

AbbVie Inc. is a American stock, trading under the symbol ABBV-N on the New York Stock Exchange (ABBV). It is usually referred to as NYSE:ABBV or ABBV-N

Is AbbVie Inc. a buy or a sell?

In the last year, 40 stock analysts published opinions about ABBV-N. 30 analysts recommended to BUY the stock. 7 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for AbbVie Inc..

Is AbbVie Inc. a good investment or a top pick?

AbbVie Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for AbbVie Inc..

Why is AbbVie Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is AbbVie Inc. worth watching?

40 stock analysts on Stockchase covered AbbVie Inc. In the last year. It is a trending stock that is worth watching.

What is AbbVie Inc. stock price?

On 2022-09-26, AbbVie Inc. (ABBV-N) stock closed at a price of $141.21.